An update on the safety and efficacy of regorafenib in the treatment of solid cancers

Bibliography

• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129(1):245-55
   PubMed Web of Science ®Google Scholar
• Lowinger TB, Riedl B, Dumas J, Smith RA. Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des 2002;8(25):2269-78
   PubMed Web of Science ®Google Scholar
• Schmieder R, Hoffmann J, Becker M, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer 2014;135(6):1487-96
   PubMed Web of Science ®Google Scholar
• Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013;12(7):1322-31
   PubMed Web of Science ®Google Scholar
• Cyran CC, Kazmierczak PM, Hirner H, et al. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One 2013;8(9):e76009
   PubMedGoogle Scholar
• Carr BI, Cavallini A, Lippolis C, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013;228(2):292-7
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18(9):2658-67
   PubMed Web of Science ®Google Scholar
• Trnkova Z, Grothey A, Sobrero A, et al. Population pharmacokinetics analysis of regorafenib and its active metabolites from the phase III CORRECT study of metastatic colorectal cancer. Ann Oncol 2013;24(Suppl 4):iv37
   Google Scholar
• Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012;13(10):1055-62
   PubMed Web of Science ®Google Scholar
• Kies M, Blumenschein G, Christensen O, et al. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol, 2010;28(Suppl 15):abstract 7585
   Google Scholar
• Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 2013;24(6):1560-7
   PubMed Web of Science ®Google Scholar
• McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8(3):371-82
   PubMed Web of Science ®Google Scholar
• Sunakawa Y, Furuse J, Okusaka T, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs 2014;32(1):104-12
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012;106(11):1722-7
   PubMed Web of Science ®Google Scholar
• Finn RS, Blumenschein G, Tolcher A, et al. Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): phase I safety and pharmacokinetic (PK) study. J Clin Oncol 2013;31(Suppl 4):abstract 300
   Google Scholar
• Clinical Pharmacology Biopharmaceutics Review on Regorafenib (Stivarga®) by, USA Food Drug Administration, NDA 203-085. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204369Orig1s000ClinPharmR.pdf
   Google Scholar
• Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216(1):64-74
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24(29):4764-74
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295-302
   PubMed Web of Science ®Google Scholar
• Serrano C, George S. Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 2014;6(3):115-27
   PubMed Web of Science ®Google Scholar
• George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012;30(19):2401-7
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Yau T, et al. CONCUR: a randomized, double-blind, placebo-controlled phase 3 study of regorafenib monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC). Ann Oncol 2014;25(Suppl 2):ii114-i15
   Google Scholar
• Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013;31(4):1078-86
   PubMed Web of Science ®Google Scholar
• Shitara K, Yamazaki K, Uetake H, et al. Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE). J Clin Oncol 2014;32(5s suppl):abstract TPS3662
   Google Scholar
• Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 2013;49(16):3412-19
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study. J Clin Oncol 2013;31(Suppl 4):abstract 467
   Google Scholar
• De Wit M, Boers-Doets CB, Saettini A, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer 2014;22(3):837-46
   PubMed Web of Science ®Google Scholar
• Khan G, Moss RA, Braiteh F, Saltzman M. Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Manag Res 2014;6:93-103
   PubMed Web of Science ®Google Scholar
• Gomes D, Hassabo HM, Al Mutar SS, et al. MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. J Clin Oncol 2014;32(Suppl 3):abstract 635
   Google Scholar
• Maruzzo M, Kollar A, Benson CA, et al. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the U.K. Managed Access Program. J Clin Oncol 2014;32(5s Suppl):abstract 10551
   Google Scholar
• Wang Z, Xu J, Nie W, et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70(2):225-31
   PubMed Web of Science ®Google Scholar